Skip to main content
Anteris Technologies Global Corp. logo

Anteris Technologies Global Corp. — Investor Relations & Filings

Ticker · AVR ISIN · US03675P1021 ASX Manufacturing
Open in API
Filings indexed 1,664 across all filing types
Latest filing 2023-04-19 Capital/Financing Update
Country US United States of America
Listing ASX AVR

About Anteris Technologies Global Corp.

https://anteristech.com/

Anteris Technologies is a structural heart company focused on the development and commercialization of medical devices for heart valve disease. Its lead product is the DurAVR® Transcatheter Heart Valve (THV), a biomimetic valve designed for patients with severe aortic stenosis. The DurAVR® THV is engineered to mimic the performance of a healthy human aortic valve, aiming to restore normal, laminar blood flow. Clinical studies have shown the device delivers a favorable hemodynamic profile, characterized by low pressure gradients and a significant reduction in prosthesis-patient mismatch (PPM), even in patients with challenging anatomies. The company is advancing its technology through pivotal clinical trials to establish a new standard in transcatheter aortic valve replacement (TAVR) and improve long-term patient outcomes.

Recent filings

Filing Released Lang Actions
Application for quotation of securities - AVR 8 pages 30.2KB
Capital/Financing Update Classification · 95% confidence The document is an application for quotation of securities on the ASX by Anteris Technologies Ltd. It details the number and type of securities to be quoted, issue dates, and compliance with listing rules. There is no financial performance data, earnings information, or management discussion. The document is a regulatory announcement related to capital markets activity, specifically the listing of new securities. This fits the category of Capital/Financing Update (CAP), as it concerns the issuance and quotation of securities and changes in capital structure.
2023-04-19 English
Agreement to Develop New Heart Valve Repair Device 4 pages 247.3KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 19 April 2023 regarding an agreement to develop a new heart valve repair device. It details the terms of a partnership agreement, including contributions, board composition, break rights, and options related to the development of medical devices. There are no financial statements, quarterly or annual results, or audit information presented. The content focuses on a strategic partnership and capital commitment for development, which aligns with updates on company financing activities or capital structure changes. The document is not a full financial report, earnings release, or management discussion, but rather an announcement of a capital/financing update related to a development agreement. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (9445 characters) supports it being a substantive announcement rather than a brief notice or report publication announcement.
2023-04-18 English
Annual Report to shareholders 92 pages 3.4MB
Regulatory Filings
2023-04-13 English
Corporate Governance Statement and Appendix 4G 22 pages 1.7MB
Governance Information Classification · 95% confidence The document is titled 'Corporate Governance Statement' and relates to the financial year ended 31 December 2022. It discusses the company's governance principles, board structure, compliance with governance recommendations, audit committee details, CEO and CFO certifications, and policies related to disclosure and communication. The content focuses on governance practices, board roles, independence, ethics, and oversight rather than financial results or operational performance. It references the Annual Report for further details but does not itself contain financial statements or detailed financial analysis. The document is comprehensive and substantive, not a brief announcement or certification. Therefore, it fits the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2023-04-13 English
Becoming a substantial holder from MUFG 18 pages 943.8KB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Form 603 Corporations Act 2001 Section 671B Notice of initial substantial holder' and details the substantial shareholding of Mitsubishi UFJ Financial Group, Inc. in Anteris Technologies Ltd. It includes voting power percentages, relevant interests, registered holders, and associates. The document is a formal notification of a substantial shareholding as required under Australian Corporations Law. It does not contain financial statements, earnings data, management discussion, or other report content. It is a notification of a major shareholding level crossing a threshold, which fits the definition of 'Major Shareholding Notification'.
2023-04-11 English
Patent for Transcatheter Heart Valve Replacement Technology 2 pages 149.3KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 12 April 2023, reporting that Anteris Technologies has received a utility patent for a novel transcatheter heart valve replacement technology. The content focuses on the patent grant and its significance for the company, with no financial data, earnings, management changes, or regulatory filings mentioned. The document is relatively short (3059 characters) and serves as a news announcement about intellectual property rather than a financial or regulatory report. Therefore, it does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. It is best classified as a general regulatory announcement about a corporate development, which falls under Regulatory Filings (RNS).
2023-04-11 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.